Dose test of a DLL3 cancer drug for neuroendocrine tumors
Part of Cancer, Lungs & breathing clinical trials.
This Phase 2 study tests how different doses of BI 764532 affect people with small cell lung cancer or certain other neuroendocrine cancers. It may help shrink tumors and improve symptoms after standard treatments have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be at least 18 years old and able to give written consent
- Have small cell lung cancer or another specified neuroendocrine cancer, and it must have been confirmed by a lab (biopsy/cytology)
- Your cancer must have gotten worse or come back after prior standard treatment (typically at least one platinum chemotherapy treatment; small cell lung cancer usually after at least two lines)
- You must be well enough to do daily activities (ECOG 0 or 1) and have at least one measurable tumor spot on a recent scan
- Have stored tumor tissue available for testing (archival tissue for Part 1; specific preserved tissue for Parts 2/3; no FNA/cytology or decalcified bone samples)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental treatment for several types of advanced cancer that have stopped responding to standard therapy. The drug targets a protein called DLL3 found on some tumor cells, which may help slow or stop tumor growth.
This Phase 1 study tests how BI 764532 moves into and through tumors in people with small-cell lung cancer or neuroendocrine cancer. It’s likely aimed at understanding the drug’s behavior in your body and tumor, especially if you’ve already tried standard treatments.
This trial tests a special PET/CT imaging scan that may help doctors find where small cell lung cancer (and some related tumors) are in the body using a DLL3 target. It’s a Phase 1/2 study, mainly to see how well the scan detects tumors and guides care.
This trial tests an investigational drug, BL-M14D1, for people with certain types of neuroendocrine tumors or small cell lung cancer that have progressed after standard treatment. The drug targets a protein called DLL3 found on these cancer cells, which may help shrink tumors or slow their growth.
This trial tests a new drug called MP0712 that delivers radiation directly to cancer cells that have a marker called DLL3. It is for people with small cell lung cancer or other solid tumors that express DLL3, whose cancer has come back after prior treatments.
This trial tests an experimental therapy (NEUK203-13) for people with neuroendocrine tumors, including small cell lung cancer, that have not responded to or stopped responding to standard treatments. It aims to see if the drug is safe and to look for early signs that it might shrink tumors, especially in people whose tumors have a specific marker called DLL3.
Hear when a new Small Cell Lung Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.